Selected article for: "cytokine release and host response"
Author: Ruiz-Rodríguez, Juan Carlos; Molnar, Zsolt; Deliargyris, Efthymios N.; Ferrer, Ricard
Title: The Use of CytoSorb Therapy in Critically Ill COVID-19 Patients: Review of the Rationale and Current Clinical Experiences
  • Cord-id: 0m4mw6ik
  • Document date: 2021_7_17
    • ID: 0m4mw6ik
    Snippet: The COVID-19 pandemic has led to the biggest global health crisis of our lifetime. There is accumulating evidence that a substantial number of critically ill COVID-19 patients exhibit a dysregulated host response manifesting as cytokine storm or cytokine release syndrome, which in turn contributes to the high observed rates of mortality. Just as in other hyperinflammatory conditions, extracorporeal cytokine removal may have potential beneficial effects in this subgroup of COVID-19 patients. The
    Document: The COVID-19 pandemic has led to the biggest global health crisis of our lifetime. There is accumulating evidence that a substantial number of critically ill COVID-19 patients exhibit a dysregulated host response manifesting as cytokine storm or cytokine release syndrome, which in turn contributes to the high observed rates of mortality. Just as in other hyperinflammatory conditions, extracorporeal cytokine removal may have potential beneficial effects in this subgroup of COVID-19 patients. The CytoSorb blood purification device is the most extensively investigated cytokine removal platform with considerable evidence suggesting that early intervention can provide rapid hemodynamic stabilization and improvement in vital organ functions. The purpose of this review is to provide an overview of the pathophysiological background of hyperinflammation in COVID-19 and to summarize the currently available evidence on the effects of hemoadsorption in these patients.

    Search related documents:
    Co phrase search for related documents
    • acute aki kidney injury and adjunctive therapy: 1
    • acute aki kidney injury and adjuvant therapy: 1
    • acute aki kidney injury and liver tissue: 1, 2
    • acute aki kidney injury and lung function: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and adequate supportive therapy: 1, 2
    • acute ards respiratory distress syndrome and adjunctive therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute ards respiratory distress syndrome and adjuvant therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute ards respiratory distress syndrome and liver tissue: 1, 2, 3
    • acute ards respiratory distress syndrome and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67
    • acute ards respiratory distress syndrome and lung function improvement: 1, 2, 3, 4
    • acute renal and adjunctive therapy: 1, 2
    • acute renal and adjuvant therapy: 1, 2
    • acute renal and liver tissue: 1
    • acute renal and lung function: 1, 2, 3, 4, 5
    • acute respiratory failure and adequate supportive therapy: 1
    • acute respiratory failure and adjunctive therapy: 1, 2, 3, 4
    • acute respiratory failure and adjuvant therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory failure and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute respiratory failure and lung function improvement: 1